Brokerages Set Maplight Therapeutics, Inc. (NASDAQ:MPLT) Price Target at $31.00

Shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) have earned a consensus rating of “Buy” from the six analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $31.00.

Several equities analysts have recently weighed in on the company. Wall Street Zen upgraded Maplight Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Jefferies Financial Group assumed coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $32.00 price objective for the company. Leerink Partnrs raised shares of Maplight Therapeutics to a “strong-buy” rating in a research note on Friday, November 21st. Morgan Stanley started coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set an “overweight” rating and a $34.00 target price for the company. Finally, Stifel Nicolaus assumed coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $28.00 price target on the stock.

Maplight Therapeutics Trading Down 8.0%

Shares of Maplight Therapeutics stock opened at $17.00 on Friday. The stock has a market cap of $771.29 million and a price-to-earnings ratio of -0.46. Maplight Therapeutics has a twelve month low of $12.24 and a twelve month high of $21.55. The company has a 50-day simple moving average of $16.90.

Maplight Therapeutics (NASDAQ:MPLT) last announced its earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.